F5055

FGFR1 (FLT2) (399-822), active, GST tagged human

PRECISIO^® Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE), buffered aqueous glycerol solution

• 别名: BFGFR, C-FGR, CD331, CEK, FLG, FLT2, KAL2, N-SAM
• 分類程式碼代碼: 51111800
• NACRES: NA.32

属性

• 重組細胞: expressed in baculovirus infected Sf9 cells
• 品質等級: 200
• 產品線: PRECISIO^® Kinase
• 化驗: ≥70% (SDS-PAGE)
• 形狀: buffered aqueous glycerol solution
• 比活性: 150-204 nmol/min·mg
• 分子量: ~73 kDa
• UniProt登錄號: P11362
• 運輸包裝: dry ice
• 儲存溫度: −70°C
• 基因資訊: human ... FGFR1(2260)

说明

一般說明

FGFR1 (fibroblast growth factor receptor 1) is one of the four variants of FGFR, the ligand of which are the FGF polypeptides. FGFRs are highly conserved in nature, and the variants differ in their intracellular kinase and extracellular ligand-binding domains. It is a receptor tyrosine kinase localized to the human chromosome 8p12.

生化／生理作用

Studies in genetically modified mice show that the epithelial-stromal interaction mediated by FGFR1 and FGF are responsible for the pathophysiology of prostate cancer. The antitumor property of dovitinib is mediated by the inhibition of FGFR1 signaling in prostate cancer to prevent bone metastasis. In malignant pleural mesothelioma (MPM), FGFR1 mRNA levels are elevated, though the gene is not amplified. FGFR1 autocrine signaling is implicated in the tumorigenesis of MPM, and thus, FGFR1 pathway has potential as a therapeutic target in the same. This gene is amplified in squamous cell lung cancer, head and neck squamous cell cancer (HNSCC) and breast cancer.

外觀

Supplied in 50 mM Tris-HCl, pH 7.5, with 150 mM NaCl, 0.2 5mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol.

法律資訊

PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany

安全信息

• 儲存類別代碼: 10 - Combustible liquids
• 水污染物質分類（WGK）: WGK 1
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable
• 個人防護裝備: Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)